Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers

Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to induction of cytochrome P450 3A by rifampin. In th...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: la Porte, C. J. L., Colbers, E. P. H., Bertz, R., Voncken, D. S., Wikstrom, K., Boeree, M. J., Koopmans, P. P., Hekster, Y. A., Burger, D. M.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology (ASM) 2004
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC400571/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15105105/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.5.1553-1560.2004
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires